Reported results from Amendment No. 3 to Form S-1, filed November 17, 2026. Key figures are unchanged from Amendment No. 2: annual figures and the 2025–2026 quarters as disclosed for revenue and operating income. Quarterly net income, operating cash flow, and capital expenditure are not broken out by quarter in the filing and are therefore omitted from the quarterly table.
Source: S-1/A Amendment No. 3. USD millions.
Source: S-1/A Amendment No. 3. USD millions.
Source: S-1/A Amendment No. 3. USD millions.
Source: S-1/A Amendment No. 3. USD millions.
| Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | Q3 2026 | |
|---|---|---|---|---|---|---|---|
| Revenue | 376 | 787 | 1,382 | 2,040 | 4,731 | 11,555 | 16,956 |
| Operating income | −935 | −1,200 | −3,089 | −2,836 | −1,667 | 974 | −567 |
| Operating margin % | −248.7 | −152.5 | −223.5 | −139 | −35.2 | 8.4 | −3.3 |
| 9M 2025 | 9M 2026 | |
|---|---|---|
| Revenue | 2,545 | 33,242 |
| Operating income | −5,224 | −1,260 |
| Net income | −25,107 | −104,039 |
| Operating cash flow | −2,024 | 6,569 |
| Purchases of PPE | 111 | 925 |
| Free cash flow | −2,135 | 5,644 |
| Cash and cash equivalents | — | 95,562 |
| Cash and short-term investments | — | 131,845 |
| Operating margin % | −205.3 | −3.8 |
| Net margin % | −986.5 | −313 |
| FCF margin % | −83.9 | 17 |
| FY2023 | FY2024 | FY2025 | |
|---|---|---|---|
| Revenue | 41 | 386 | 4,585 |
| Operating income | −551 | −2,980 | −8,060 |
| Net income | −1,531 | −8,309 | −41,965 |
| Operating cash flow | −1,627 | −5,692 | −2,637 |
| Purchases of PPE | 2 | 15 | 131 |
| Free cash flow | −1,629 | −5,707 | −2,768 |
| Cash and cash equivalents | — | 3,141 | 17,388 |
| Cash and short-term investments | — | 3,141 | 20,277 |
| Operating margin % | −1,343.9 | −772 | −175.8 |
| Net margin % | −3,734.1 | −2,152.6 | −915.3 |
| FCF margin % | −3,973.2 | −1,478.5 | −60.4 |
Data file: financials.json